What’s Going On With Enphase Stock Today?

Enphase Energy, Inc. (NASDAQ: ENPH) shares are lower today. The company announced that installers of Enphase products in Brasilia have seen a significant rise in deployments of residential solar energy systems.

Enphase Energy, Inc. (NASDAQ:ENPH) shares are lower today. The company announced that installers of Enphase products in Brasilia have seen a significant rise in deployments of residential solar energy systems.

What To Know: The increase is powered by IQ7AM Microinverters which utilize Enphase’s unique software-defined architecture and semiconductor integration for excellent reliability and economies of scale. It is purported that they also simplify solar system design and streamline installation to reach the benefits of solar power faster and more efficiently.

“After selling our first Enphase system installation in June 2022, we made the switch to offer Enphase products exclusively due to the strength of the company’s best-in-class technology, customer support, and installer services,” said Murilo Vidigal, project director at Mavo Engenharia. “Our customers with Enphase-powered solar systems report great peace of mind thanks to a reduced need for ongoing maintenance and a highly customizable design that allows them the opportunity to grow their system as their energy needs evolve.”

Related Link: Zscaler’s Market-Leading Position in Zero Trust Initiatives, Impressive AI Integration: Analysts Take on Future Growth

ENPH Price Action: Shares of ENPH were down 5.88% at $171.12 at the time of publication, according to Benzinga Pro.

Image by Leopictures from Pixabay

Total
0
Shares
Related Posts
Read More

Verve Therapeutics Announces Interim Data For VERVE-101 Demonstrating First Human Proof-Of-Concept For In Vivo Base Editing With Dose-Dependent Reductions In LDL-C And Blood PCSK9 Protein In Patients With Heterozygous Familial Hypercholesterolemia

LDL-C Reductions Up to 55% and Blood PCSK9 Protein Reductions Up to 84% Observed After a Single Infusion of VERVE-101 at Potentially Therapeutic Doses Safety Profile Supports Continued Development of

VERV